Coterra Energy Inc. (CTRA - $28.06) and Devon Energy Corp. (DVN - $39.94)News Reports Companies Near Potential Tie-Up to Create $60 Billion US Shale Group. According to the Financial Times, CTRA and DVN are in advanced talks about a combination that would create one of the largest oil and natural g
A director at Gilead Sciences Inc sold 10,000 shares at 139.891USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
SkyWater Technology Inc. (SKYT - $31.32) and IonQ, Inc. (IONQ - $47.25)Announces $1.8 Billion Cash & Stock Acquisition; Offer Value $35.00/share ($15 Cash + $20 Stock, Subject to Collar); Expected Close 2/3Q' 2026. IONQ announced on January 26, 2026, that it has entered into a definitive agreem
Amicus Therapeutics Inc. (NASDAQ: FOLD - $14.35) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN - $56.77)Filed Preliminary Proxy; Highlights From Background of Merger Agreement. FOLD filed its preliminary proxy with details regarding the background of BMRN's acquisition of FOLD, beginning with FOLD
According to SNY, the 61.2% increase from 2023 was primarily due to patient conversion from Lumizyme (available as Myozyme outside the U.S.), and Nexviazyme sales represented approximately 49% of SNY's total Pompe disease franchise sales by YE24. BMRN sees the early launch phase of PomOp as a uniqu
Coasting as We Stalk for Buying Opportunity; Downgrading Discretionary to Underweight We had been near-term bullish on the S&P 500 (SPX) since our 4/22/25 Compass, however, we are officially downgrading our near-term outlook to neutral. The SPX, Nasdaq 100 (QQQ), and Russell 2000 (IWM) are breaking below their 50-day MAs and are also violating their multi-month uptrends, signaling a consolidation period is here. With that said, our intermediate-term outlook remains bullish (as of our 5/14/25 Co...
A director at Merck & Co Inc sold 7,085 shares at 87.000USD and the significance rating of the trade was 94/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.